We are live on ! Find out more
GNRX

VanEck Vectors Generic Drugs ETF
GNRX

Delisted

GNRX was delisted on the 4th of April, 2019.

Back to rankings

4 hedge funds and large institutions have $703K invested in VanEck Vectors Generic Drugs ETF in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

476% more capital invested

Capital invested by funds: $122K → $703K (+$581K)

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$548K

Top Sellers

Rank Fund Capital Flow
1
NFG
Next Financial Group
Texas
-$6K
2
LTFS
Ladenburg Thalmann Financial Services
Florida
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$558K +$548K +24,687 New
UBS Group
2
UBS Group
Switzerland
$68K – – –
IA
3
IFP Advisors
Florida
$51K – – –
FDCDDQ
4
Federation des caisses Desjardins du Quebec
Quebec, Canada
$25.7K +$25.3K +1,141 New
NFG
5
Next Financial Group
Texas
– -$6K -300 Closed
LTFS
6
Ladenburg Thalmann Financial Services
Florida
– -$4K -200 Closed

GNRX Hedge Fund Activity: Q1 2017 in Review

4 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q1 2017, worth a combined $703K — up 476% from $122K a quarter earlier.

Fund positioning in GNRX was balanced in Q1 2017: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $548K. The largest seller was Next Financial Group, exiting entirely with an estimated $6K sold.

  • 4 institutional investors held VanEck Vectors Generic Drugs ETF (GNRX) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $703K of VanEck Vectors Generic Drugs ETF stock for Q1 2017, up 476% quarter-over-quarter.
  • 2 funds opened new VanEck Vectors Generic Drugs ETF positions in Q1 2017 and 2 closed out, a net change of 0 holders.
  • The largest VanEck Vectors Generic Drugs ETF buyer in Q1 2017 was Citadel Advisors, an estimated $548K added.
  • The largest VanEck Vectors Generic Drugs ETF seller in Q1 2017 was Next Financial Group, an estimated $6K sold.

Based on aggregated 13F filings for Q1 2017.